Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shufeng Zhike Mixture
- Development stage
- Phase 3
- Lead developer
- West China Hospital of Sichuan University
- Administration
- Oral
01
Overview
Shufeng Zhike Mixture is a Traditional Chinese Medicine (TCM) liquid formulation developed by West China Hospital of Sichuan University. It is primarily indicated for the treatment of post-infectious cough (PIC), specifically for patients presenting with the TCM syndrome of "wind-pathogen lingering in the lung" (fengxie luan fei). The formulation is designed to dispel wind, ventilate the lung, and alleviate coughing symptoms. As a hospital-made preparation (院内制剂), it has undergone clinical evaluation in a randomized, double-blind, placebo-controlled Phase 3 trial to establish its efficacy and safety profile in adult populations suffering from persistent cough following respiratory infections.
- Other names
- 疏风止咳合剂
Beyond the preview
Go deeper on Shufeng Zhike Mixture.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shufeng Zhike Mixture.